Century Therapeutics’ $242.7 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in the offering.

Century Therapeutics, Inc. executed the $242.7 million initial public offering of 12,132,500 shares of Class A common stock of, which included 1,582,500 shares from the full exercise of the underwriters’ option to purchase additional shares. Century is traded on the Nasdaq Global Select Market under the trading symbol “IPSC.”

J.P. Morgan Securities LLC, BofA Securities, Inc., SVB Leerink LLC, and Piper Sandler & Co. acted as joint book-running managers of the offering and representatives of the underwriters.

Century is a biotechnology company utilizing a comprehensive cell therapy platform to develop transformative allogeneic cell therapies with the potential to create products for the treatment of both solid tumor and hematological malignancies. 

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. (Picture) and Roshni Banker Cariello and associates Arisa Akashi and Aaron Shubert. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and Brette L. Trost. The tax team included counsel Kiara L. Rankin and associate Dov Sussman. Counsel Marcie A. Goldstein provided FINRA advice. 

Involved fees earner: Aaron Shubert – Davis Polk & Wardwell; Arisa Akashi – Davis Polk & Wardwell; Roshni Banker Cariello – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Kiara Rankin – Davis Polk & Wardwell; Dov Sussman – Davis Polk & Wardwell; Brette Trost – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Bank of America Securities; J.P. Morgan Securities LLC; Piper Sandler; SVB Leerink LLC;

Author: Martina Bellini